Bobak Azamian Sells 10,972 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Bobak Azamian sold 10,972 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $69.42, for a total value of $761,676.24. Following the sale, the chief executive officer owned 57,052 shares in the company, valued at $3,960,549.84. The trade was a 16.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Tarsus Pharmaceuticals Stock Down 2.2%

Shares of Tarsus Pharmaceuticals stock traded down $1.49 during trading on Thursday, reaching $66.75. The company’s stock had a trading volume of 461,600 shares, compared to its average volume of 672,393. The stock has a 50-day moving average price of $69.59 and a two-hundred day moving average price of $70.20. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.82 and a current ratio of 3.85. Tarsus Pharmaceuticals, Inc. has a one year low of $38.51 and a one year high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The company had revenue of $151.67 million during the quarter, compared to analyst estimates of $144.56 million. Analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Lifesci Capital upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Monday. Zacks Research lowered Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Barclays initiated coverage on Tarsus Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $100.00 price target on the stock. Finally, Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $91.83.

Key Stories Impacting Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published a set of 2026 estimates that materially narrow expected losses (FY2026 now seen at -$1.01 vs. broader consensus -$3.17) and forecast a positive Q4‑2026 EPS of $0.09 — a clear bullish catalyst that can support upside expectations. Lifesci upgrade report
• Positive Sentiment: Large institutional investors have been increasing stakes (RTW, Deep Track, Jennison, Vanguard, Morgan Stanley among others), keeping roughly 90% institutional ownership — steady buying from big funds tends to support share-price stability and upside over time. MarketBeat TARS coverage
• Neutral Sentiment: Analyst consensus remains mixed‑to‑favorable: the average recommendation is “Moderate Buy” and some firms (Guggenheim, Oppenheimer) have raised targets while others are more cautious — this keeps the outlook constructive but not unanimous. Analyst consensus article
• Neutral Sentiment: Recent quarterly results: revenue beat estimates ($151.7M vs. $144.6M) but EPS slightly missed ($0.20 loss vs. $0.19 expected). Revenue strength is supportive; continued negative margins and guidance keep risk elevated until pipeline milestones materialize. Earnings summary
• Negative Sentiment: Insider selling: Director William J. Link sold 12,500 shares at an average $68.79 on March 16 (disclosed via SEC filing), reducing his stake by ~9.7%. Insider sales can create short‑term downward pressure or be interpreted by some investors as profit‑taking. InsiderTrades report (SEC Form 4)

Institutional Trading of Tarsus Pharmaceuticals

A number of institutional investors have recently bought and sold shares of TARS. Rockefeller Capital Management L.P. raised its position in shares of Tarsus Pharmaceuticals by 15.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after acquiring an additional 172 shares during the last quarter. State of Wisconsin Investment Board boosted its position in shares of Tarsus Pharmaceuticals by 1.1% in the 4th quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company’s stock worth $2,613,000 after purchasing an additional 332 shares during the last quarter. Federated Hermes Inc. boosted its position in shares of Tarsus Pharmaceuticals by 0.6% in the 2nd quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock worth $2,229,000 after purchasing an additional 339 shares during the last quarter. Valeo Financial Advisors LLC grew its stake in shares of Tarsus Pharmaceuticals by 11.1% during the fourth quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock worth $321,000 after purchasing an additional 392 shares during the period. Finally, Creative Planning increased its holdings in Tarsus Pharmaceuticals by 3.3% in the third quarter. Creative Planning now owns 12,367 shares of the company’s stock valued at $735,000 after purchasing an additional 393 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.